Sacubitril/valsartan in advanced heart failure with reduced ejection fraction: rationale and design of the LIFE trial

DL Mann, SJ Greene, MM Givertz, JM Vader… - Heart Failure, 2020 - jacc.org
Abstract The PARADIGM-HF (Prospective Comparison of Angiotensin II Receptor Blocker
Neprilysin Inhibitor With Angiotensin-Converting Enzyme Inhibitor to Determine Impact on …
被引用次数：59 相关文章

Sacubitril/Valsartan in Advanced Heart Failure With Reduced Ejection Fraction: Rationale and Design of the LIFE Trial

DL Mann, SJ Greene, MM Givertz… - JACC: Heart …, 2020 - researchworks.creighton.edu
The PARADIGM-HF (Prospective Comparison of Angiotensin II Receptor Blocker Neprilysin
Inhibitor With Angiotensin-Converting Enzyme Inhibitor to Determine Impact on Global …
[HTML] nih.gov

[HTML][HTML] Sacubitril/Valsartan in Advanced Heart Failure With Reduced Ejection Fraction: Rationale and Design of the LIFE Trial

DL Mann, SJ Greene, MM Givertz, JM Vader… - Jacc. Heart …, 2020 - ncbi.nlm.nih.gov
Abstract The PARADIGM-HF (Prospective Comparison of Angiotensin II Receptor Blocker
Neprilysin Inhibitor With Angiotensin-Converting Enzyme Inhibitor to Determine Impact on …

Sacubitril/Valsartan in Advanced Heart Failure With Reduced Ejection Fraction: Rationale and Design of the LIFE Trial

DL Mann, SJ Greene, MM Givertz, JM Vader… - 2020 - pubmed.ncbi.nlm.nih.gov
The PARADIGM-HF (Prospective Comparison of Angiotensin II Receptor Blocker Neprilysin
Inhibitor With Angiotensin-Converting Enzyme Inhibitor to Determine Impact on Global …

Sacubitril/Valsartan in Advanced Heart Failure With Reduced Ejection Fraction: Rationale and Design of the LIFE Trial.

DL Mann, SJ Greene, MM Givertz, JM Vader… - JACC. Heart …, 2020 - europepmc.org
Abstract The PARADIGM-HF (Prospective Comparison of Angiotensin II Receptor Blocker
Neprilysin Inhibitor With Angiotensin-Converting Enzyme Inhibitor to Determine Impact on …
[HTML] sciencedirect.com

[HTML][HTML] Sacubitril/Valsartan in Advanced Heart Failure With Reduced Ejection Fraction: Rationale and Design of the LIFE Trial

DL Mann, SJ Greene, MM Givertz, JM Vader… - JACC: Heart Failure, 2020 - Elsevier
Abstract The PARADIGM-HF (Prospective Comparison of Angiotensin II Receptor Blocker
Neprilysin Inhibitor With Angiotensin-Converting Enzyme Inhibitor to Determine Impact on …

Sacubitril/Valsartan in Advanced Heart Failure With Reduced Ejection Fraction: Rationale and Design of the LIFE Trial

LIFE Investigators - JACC: Heart Failure, 2020 - pure.johnshopkins.edu
Abstract The PARADIGM-HF (Prospective Comparison of Angiotensin II Receptor Blocker
Neprilysin Inhibitor With Angiotensin-Converting Enzyme Inhibitor to Determine Impact on …

Sacubitril/Valsartan in Advanced Heart Failure With Reduced Ejection Fraction: Rationale and Design of the LIFE Trial

LIFE Investigators - JACC: Heart Failure, 2020 - profiles.wustl.edu
Abstract The PARADIGM-HF (Prospective Comparison of Angiotensin II Receptor Blocker
Neprilysin Inhibitor With Angiotensin-Converting Enzyme Inhibitor to Determine Impact on …
[PDF] researchgate.net

[PDF][PDF] Sacubitril/Valsartan in Advanced Heart Failure With Reduced Ejection Fraction

DL Mann, SJ Greene, MM Givertz, JM Vader… - 2020 - researchgate.net
ABSTRACT The PARADIGM-HF (Prospective Comparison of Angiotensin II Receptor
Blocker Neprilysin Inhibitor With Angiotensin-Converting Enzyme Inhibitor to Determine …

Sacubitril/Valsartan in Advanced Heart Failure With Reduced Ejection Fraction: Rationale and Design of the LIFE Trial

LIFE Investigators - JACC: Heart Failure, 2020 - mayoclinic.elsevierpure.com
Abstract The PARADIGM-HF (Prospective Comparison of Angiotensin II Receptor Blocker
Neprilysin Inhibitor With Angiotensin-Converting Enzyme Inhibitor to Determine Impact on …